Literature DB >> 6116682

Clinical pharmacokinetics of the eye. Proctor lecture.

S Mishima.   

Abstract

Pharmacokinetics of instilled drugs in the human eye is reviewed. The behavior of drugs in the conjunctival cul-de-sac is discussed, and the loss rates with various vehicles are estimated. Kinetics of intraocular drug penetration follows the same pattern in human and rabbit eyes. From results of rabbit experiments, various pharmacokinetic coefficients are computed, including the permeability of the corneal epithelium. Also, with use of published data in human aqueous, the corneal permeability, apparent absorption, and elimination rate constants are calculated for some drugs in the human eye. From the anesthetic response of the cornea the apparent elimination rate constants of the surface anesthetics are obtained. The pupil response is converted to a response parameter proportional to the biophase drug concentration. The time course of its changes conforms with the kinetics of intraocular drug penetration, and the apparent absorption and elimination rate constants are computed for various drugs. The latter constant becomes smaller with increased ocular pigmentation. Use of the relative bioavailability concept permits comparison of drug absorption efficiency among various vehicles. Pharmacokinetic coefficients are also obtained for the cycloplegic responses. The intraocular pressure response is analyzed, and it is suggested that the reduction ratio in the outflow pressure, outflow resistance, and the aqueous formation rate be used for dose-response studies. The rate of effect disappearance is defined and is given for three beta-adrenergic blocking agents.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6116682

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  26 in total

1.  Penetration of engineered antibody fragments into the eye.

Authors:  M A Thiel; D J Coster; S D Standfield; H M Brereton; C Mavrangelos; H Zola; S Taylor; A Yusim; K A Williams
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

2.  Dosing problems in the use of topical ophthalmic drops.

Authors:  A Loewenstein; O Geyer; A Blanc; M Lazar
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1992       Impact factor: 3.117

3.  Minimally invasive, direct, real time measurement of drug concentration in the anterior eye.

Authors:  J Miller; W S Wilson; C G Wilson; D Uttamchandani
Journal:  Br J Ophthalmol       Date:  2005-09       Impact factor: 4.638

4.  Corneal permeability assay of topical eye drop solutions in rabbits by MRI.

Authors:  Xiaochun Mao; Shaowei Zhang; Hui Hen; Longting Du; Guigang Li; Bin Li; Hong Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-12-22

5.  Resistance to fluoroquinolones and methicillin in ophthalmic isolates of Staphylococcus pseudintermedius from companion animals.

Authors:  Min-Hee Kang; Min-Joo Chae; Jang-Won Yoon; So-Young Lee; Jong-Hyun Yoo; Hee-Myung Park
Journal:  Can Vet J       Date:  2014-07       Impact factor: 1.008

6.  Intraocular penetration of vancomycin eye drops after application to the medial canthus with closed lids.

Authors:  Y Alster; L Herlin; M Lazar; A Loewenstein
Journal:  Br J Ophthalmol       Date:  2000-03       Impact factor: 4.638

7.  Lyophilisates for drug delivery in ophthalmology: pharmacokinetics of fluorescein in the human anterior segment.

Authors:  S Dinslage; M Diestelhorst; A Weichselbaum; R Süverkrüp
Journal:  Br J Ophthalmol       Date:  2002-10       Impact factor: 4.638

8.  Rational use of the fixed combination of dorzolamide - timolol in the management of raised intraocular pressure and glaucoma.

Authors:  Jason Yeh; Daniel Kravitz; Brian Francis
Journal:  Clin Ophthalmol       Date:  2008-06

Review 9.  A feasibility study of using biodegradable magnesium alloy in glaucoma drainage device.

Authors:  Xiang-Ji Li; Lin Xie; Fu-Sheng Pan; Yong Wang; Hong Liu; Yu-Rong Tang; Cindy Ml Hutnik
Journal:  Int J Ophthalmol       Date:  2018-01-18       Impact factor: 1.779

10.  Daily costs of prostaglandin analogues as monotherapy or in fixed combinations with timolol, in Denmark, Finland, Germany and Sweden.

Authors:  Anders Bergström; Frédérique Maurel; Claude Le Pen; Emilie Lamure; Michael Kent; Isabelle Bardoulat; Gilles Berdeaux
Journal:  Clin Ophthalmol       Date:  2009-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.